Personalized Neoantigen Peptide Vaccine
Advanced Tumors
Seqker Biosciences, Inc.vaccinePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Advanced Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ezobresib Bristol-Myers Squibb | Phase 1/2 | CCC |
hh2710 Haihe Biopharma Co., Ltd. | Phase 1/2 | CCC |
hlx301 Shanghai Henlius Biotech | Phase 1/2 | CCC |
Cpi-100 Coordination Pharmaceuticals, Inc. | Phase 1 | CC |
Cpi-300 Coordination Pharmaceuticals, Inc. | Phase 1 | CC |
cdp1 Dragonboat Biopharmaceutical Company Limited | Phase 1 | CC |
Same molecule, other indications
Personalized Neoantigen Peptide Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →